Skip Navigation


International Immunology Advance Access originally published online on July 5, 2004
International Immunology 2004 16(8):1125-1131; doi:10.1093/intimm/dxh114
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/8/1125    most recent
dxh114v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Zafirova, Y.
Right arrow Articles by Kalfin, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zafirova, Y.
Right arrow Articles by Kalfin, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2004 The Japanese Society for Immunology

ORIGINAL RESEARCH PAPERS

Antiarthritic effect of VIP in relation to the host resistance against Candida albicans infection

Yana Zafirova1, Martin Yordanov2 and Reni Kalfin1

1 Laboratory of Neuropeptides, Institute of Physiology, Bulgarian Academy of Sciences, 23 G. Bonchev Str., 1113 Sofia, Bulgaria
2 Department of Immunology, Institute of Microbiology, 26 G. Bonchev Str., 1113 Sofia, Bulgaria

Correspondence to: R. Kalfin; E-mail: rkalfin{at}hotmail.com

Vasoactive intestinal peptide (VIP) is one of the prospective candidates for clinical application in rheumatoid arthritis (RA). Its antiarthritic effect is associated with the suppression of inflammatory and autoimmune responses. The ability of VIP to trigger a shift towards Th2 immunity suggests that anti-infectious host resistance might be affected. In the present study VIP was applied at the initiation and at the established phase of collagen-induced arthritis (CIA). Mice developed Th2 dominant anti-collagen response. The susceptibility to primary and secondary Candida albicans infection was determined after VIP administration at the established CIA. The percentage of survivors, kidney colonization, cytokine secretion by splenocytes and specific antibody synthesis were assessed. Reduced TNF-{alpha} production but not IFN-{gamma} and IL-10 was observed after the first challenge with the pathogen in CIA mice treated with VIP while the percentage of survivors was not significantly changed. The adaptive immune response was impaired in VIP-treated mice as they were more susceptible to reinfection, showed increased kidney colonization and suppressed anti-Candida IgG antibody production.

Keywords: anti-infectious resistance, cytokines, collagen-induced arthritis

Transmitting editor: G. Trinchieri


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
E. Gonzalez-Rey, P. Anderson, and M. Delgado
Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy
Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii70 - iii76.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.